Tango Therapeutics Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $201.08 (market cap $37.46B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 10× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| TNGX | TTWO | |
|---|---|---|
Market Cap | $3.75B | $37.46B |
Volume | 9,619,106 | 5,201,670 |
Sector | Health | Technology |
52-Week High | $32.90 | $262.29 |
52-Week Low | $7.50 | $189.69 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $2.77B | $38.57B |
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Take-Two Interactive (TTWO) trades at $201.23, down 3.63% today amid mixed technical signals and volatile earnings performance. The stock shows strong analyst support with 79% buy ratings and a $292.30 consensus price target, representing 45% upside potential. Recent quarterly results have been inconsistent with two beats and one miss, while the company maintains anticipation for Grand Theft Auto VI's November 2026 launch. Fundamentals reveal significant losses with a -79.51% net margin in 2025, though revenue growth continues and cash position remains strong at $1.47 billion.
The investment case hinges on GTA VI's successful execution, with current valuation reflecting high expectations. While analyst optimism remains strong, investors face risks from execution missteps, competitive pressures, and the stock's premium valuation multiples. The substantial negative earnings and cash flow volatility require careful monitoring, though institutional ownership trends show continued confidence in the long-term gaming franchise strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →